TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9609609
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline therapy
Study: 1315825
Drug: Candoxatril 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 200 mg
Study: 31147306
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon pump (IABP) 50 mL
Study: 20227053
Drug: Rescue antenatal
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue antenatal steroids
Study: 26459347
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia plus postoperative intravenous analgesia
Study: 21212157
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg BIBF 1120 b.i.d.
Study: 21212157
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg BIBF 1120 b.i.d.
Study: 21212157
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 (both doses)
Study: 15153206
Drug: Double-breath (DB)
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-breath (DB) VC inhalation induction with 8% sevoflurane in 66% nitrous oxide
Study: 15153206
Drug: Single-breath (SB)
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-breath (SB) VC inhalation induction with 8% sevoflurane in 66% nitrous oxide
Study: 11409130
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (GS) 500 mg tid
Study: 11409130
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg tid
Study: 9773910
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (2 mg/kg/day) for 3 days
Study: 1662885
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg
Study: 3079005
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg twice daily, administered intramuscularly)
Study: 3079005
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5,000 IU thrice daily, administered subcutaneously)
Study: 3079005
Drug: ASA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (100 mg on alternate days, administered orally)
Study: 3113147
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration
Study: 31899878
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan administration
Study: 31899878
Drug: No sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No sumatriptan administration (Control)
Study: 25733626
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) consumption (2 g PS/d for 28 days)
Study: 25733626
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) consumption (2 g PS/d for 28 days) in LS individuals
Study: 25733626
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) consumption (2 g PS/d for 28 days) in HS individuals
Study: 25733626
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) consumption (2 g PS/d for 28 days) in LS participants
Study: 23256446
Drug: 12‐week honey
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐week honey consumption (0.5 mL/kg body weight per day)
Study: 15620485
Drug: Swanson implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swanson implants
Study: 17065118
Drug: NeuFlex implants
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NeuFlex implants
Study: 16493482
Drug: Otamixaban (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (0.3 mg/kg)
Study: 16493482
Drug: Otamixaban (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (0.5 mg/kg)
Study: 16493482
Drug: Otamixaban (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (0.3 mg/kg) with ASA (300 mg once a day)
Study: 16493482
Drug: Otamixaban (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (0.5 mg/kg) with ASA (300 mg once a day)
Study: 16493482
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (300 mg once a day)
Study: 2455840
Drug: Xamoterol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol, 200 mg
Study: 2455840
Drug: Prenalterol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol, 50 mg
Study: 2455840
Drug: Salbutamol, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol, 8 mg
Study: 2455840
Drug: ICI 118,551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551, 25 mg with Xamoterol
Study: 2455840
Drug: ICI 118,551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551, 25 mg with Prenalterol
Study: 2455840
Drug: ICI 118,551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551, 25 mg with Salbutamol
Study: 25514106
Drug: Denosumab, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab, 60 mg s.c. every 6 months
Study: 25514106
Drug: Oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonates (ibandronate or risedronate, 150 mg once monthly for 12 months)
Study: 14984226
Drug: zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolmitriptan 2.5 mg
Study: 15259834
Drug: Citalopram, 20
Normalized name: Escitalopram, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram, 20 mg/day
Study: 9125637
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg capsule with water
Study: 9125637
Drug: Omeprazole granules
Normalized name: omeprazole Granules for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole granules with Alka-Seltzer solution
Study: 8238221
Drug: Carteolol 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 1.0% (one drop twice daily in both eyes)
Study: 8238221
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% (one drop twice daily in both eyes)
Study: 3517284
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g/d)
Study: 3517284
Drug: Phenobarbital (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (7.5 to 10 mg/kg/d)
Study: 30425469
Drug: CHF6001 (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 (20, 100, 200, 400, 800, 1,600, and 2,000 µg) via SDDPI
Study: 30425469
Drug: CHF6001 (2,400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 (2,400, 4,000, and 4,800 µg) via MDDPI
Study: 30425469
Drug: CHF6001 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 (100, 300, 600, 1,200, and 1,600 µg) once daily via SDDPI
Study: 30425469
Drug: CHF6001 (1,200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 (1,200, 2,000, or 2,400 µg) twice daily via MDDPI
Study: 17852636
Drug: Methotrexate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15 mg) + Betamethasone (3 mg) weekly
Study: 17852636
Drug: Methotrexate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15 mg) weekly
Study: 16051542
Drug: Qi-therapy (external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-therapy (external Qigong) for four weeks
Study: 16051542
Drug: Qi-therapy (external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-therapy (external Qigong)
Study: 10024861
Drug: Staples, close
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staples, close after protamine administration
Study: 11563407
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral fosinopril
Study: 11563407
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg IV fosinoprilat
Study: 1854169
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 to 300 mg every 12 h)
Study: 6364886
Drug: Mesterolone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone (75 mg/day)
Study: 10335764
Drug: Low-dose atorvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atorvastatin (20 mg)
Study: 26147898
Drug: Ethanol at
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol at BAC of approximately 0.5 g/L
Study: 26147898
Drug: Ethanol at
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol at BAC of approximately 0.9 g/L
Study: 26147898
Drug: Sober condition
Normalized name: suberic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sober condition (0 g/L BAC)
Study: 23567376
Drug: Telehealth problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth problem-solving therapy (tele-PST)
Study: 22819521
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 μg/d
Study: 22819521
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 μg/d plus montelukast 10 mg/d
Study: 17894791
Drug: Augmented transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented transfusion strategy (transfusion of 2 units of RBCs when Hb < 120 g/L)
Study: 17894791
Drug: Standard transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard transfusion strategy (transfusion of 2 units of RBCs when Hb < 80 g/L)
Study: 10486649
Drug: No estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: No estrogen replacement therapy (Control)
Study: 8564101
Drug: Terbutaline 7.5
Normalized name: terbutaline 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 7.5 mg twice a day for 2 weeks
Study: 8564101
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 micrograms twice a day by inhalation
Study: 8564101
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg orally 12 h before second examination
Study: 8564101
Drug: Terbutaline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline treatment
Study: 1920340
Drug: Nifedipine AR
Normalized name: nifedipine Extended Release Oral Tablet [Adalat AR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine AR (20 mg twice daily)
Study: 1920340
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tab twice daily)
Study: 31792485
Drug: Combined orthodontic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orthodontic treatment and conventional periodontal splint (experimental group)
Study: 19852337
Drug: Elective re-siting
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective re-siting of intravenous cannulae every 48 hours
Study: 17572322
Drug: 1-minute group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 1 minute)
Study: 17572322
Drug: 2-minute group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 2 minutes)
Study: 17572322
Drug: 3-minute group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 3 minutes)
Study: 17572322
Drug: 5-minute group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-minute group (2 L/min oxygen and 4 L/min nitrous oxide for 5 minutes)
Study: 12199264
Drug: Gabapentin (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,800 to 3,600 mg/day)
Study: 9667260
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6 for six courses, administered every 28 days
Study: 9667260
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 12 for four courses, administered every 28 days
Study: 15374499
Drug: Centrophenoxine (CPH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrophenoxine (CPH), 2 g/day for 8 weeks
Study: 30426525
Drug: Hand cream
Normalized name: TETRIX HAND CREAM,TOP
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand cream dispensers equipped with an electronic system to monitor use, communicated regularly to HCWs via posters.
Study: 25743732
Drug: Muscle strength
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle strength training program (50 minutes, twice a week for 8 weeks, including Kegel's exercise, Thera-band training, and indoor walking)
Study: 19699385
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (daily dose > 1200 mg or single dose > 600 mg within 4 hours of contrast exposure)
Study: 15211249
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid administered for 7 days
Study: 21078196
Drug: Child-focused cognitive-behavioral
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive-behavioral therapy (CBT)
Study: 9874902
Drug: Child-focused cognitive-behavioral
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive-behavioral therapy (CBT) plus parental anxiety management (CBT + PAM)
Study: 9874902
Drug: Child-focused cognitive-behavioral
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive-behavioral therapy (CBT + PAM)
Study: 7979494
Drug: Nebuhaler (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler (750 ml)
Study: 7979494
Drug: Aerochamber (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerochamber (140 ml)
Study: 7979494
Drug: Babyspacer (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Babyspacer (260 ml)
Study: 403557
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg per os)
Study: 403557
Drug: Marihuana (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marihuana (10 mg delta9-THC)
Study: 14705107
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation and physical therapy (SCS+PT)
Study: 9259358
Drug: Increased dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dialysis volume (0.5 L per exchange, total increase of 1.5 L daily)
Study: 9259358
Drug: Unchanged dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged dialysis regimen (4 exchanges of 2 L per day)
Study: 8279841
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of cyclophosphamide for 3 months
Study: 8279841
Drug: Cyclophosphamide 500
Normalized name: cyclophosphamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 500 mg/m2 + CDDP 75 mg/m2 every 4 weeks for 3 courses
Study: 8279841
Drug: CP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP therapy (cyclophosphamide 600 mg/m2 + CDDP 75 mg/m2)
Study: 16806
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg
Study: 2979681
Drug: Aspirin (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1300 mg, 36 mmol)
Study: 2979681
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for aspirin (36 mmol HCl)
Study: 22639135
Drug: Levobupivacaine labor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine labor epidural (bolus concentration 0.25 % or less; infusion concentration 0.125 % or less)
Study: 22639135
Drug: Combined spinal‐epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal‐epidural procedure (morphine 0.20 mg, fentanyl 25 µg and hyperbaric bupivacaine 2.5 mg)
Study: 17707079
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (PA at baseline and FI at 3 months)
Study: 17707079
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (FI at baseline and PA at 3 months)
Study: 16883901
Drug: Chemotherapy (Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Western group)
Study: 16883901
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of TCM and chemotherapy (Integrative group)
Study: 12823702
Drug: 15% EDTAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% EDTAC solution
Study: 10608756
Drug: Antenatal zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal zidovudine treatment for 2 weeks
Study: 10608756
Drug: Antenatal zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal zidovudine treatment
Study: 1514169
Drug: Heparin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (500 U heparin/h for 30 h)
Study: 6370007
Drug: Antacid (usually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (usually Mylanta II)
Study: 22671310
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser therapy
Study: 31246661
Drug: Promestriene (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promestriene (10 mg intravaginal cream 3 times a week)
Study: 29467849
Drug: IMRT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT combined with chemotherapy
Study: 25428394
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy and chemotherapy
Study: 17481836
Drug: Sweat patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweat patches worn for 7 days after cessation of cannabis use
Study: 17481836
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of up to 14.8 mg THC/day for five consecutive days
Study: 11938417
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human erythropoietin 200 U/kg/day and iron 1mg/kg/day
Study: 10484096
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (trained twice)
Study: 2198378
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg xipamide/day
Study: 2198378
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg spironolactone/day combined with 40 mg of furosemide every other day
Study: 602716
Drug: Dexamethasone (Decadron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Decadron, 2 mg 3 times a day for 4 days)
Study: 602716
Drug: Control (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (64 patients, no treatment mentioned)
Study: 30041167
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (ICBT) for 12 weeks
Study: 26044872
Drug: Budesonide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (2 mg/day)
Study: 18765950
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A 0.05% (tCsA) eye drops
Study: 18765950
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (tCsA) and Control group
Study: 16846555
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (180 microg)
Study: 16846555
Drug: Levalbuterol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol and racemic albuterol
Study: 14984495
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection (UKALL X protocol, n = 40)
Study: 14984495
Drug: Infusion (UKALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion (UKALL XI protocol, n = 71)
Study: 11713062
Drug: Initial medical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medical therapy
Study: 30428290
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg per day for 14 days, then 20 mg per day for 14 days)
Study: 25760973
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to chemotherapy (cisplatin and paclitaxel)
Study: 16524859
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg orally 3 times a day)
Study: 10606839
Drug: Cimetidine 100
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 100 mg twice daily
Study: 9105568
Drug: E2/NETA (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (continuous oral 17 beta‐estradiol 2 mg/day combined with norethisterone acetate 1 mg/day)
Study: 9105568
Drug: E2/MPA (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/MPA (transdermal 17 beta‐estradiol 50 micrograms/day combined with cyclic medroxyprogesterone acetate 10 mg/day)
Study: 8622034
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (no BRT)
Study: 3084269
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose infusion for 2 hours
Study: 3084269
Drug: 8% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% amino acid infusion for 2 hours
Study: 11844036
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (control)